When was Avacta founded?

Avacta was founded in 2006 and raised its 1st funding round 5 years after it was founded.

Where is Avacta located?

Avacta is headquartered in London, United Kingdom. It is registered at THE COMPANY SECRETARY,UNIT 20 ASH WAY,THORP ARCH ESTATE,WETHERBY,ENGLAND,LS23 7FA.

How many employees does Avacta have?

As of Sep 30, 2026, the latest employee count at Avacta is 48.

Is Avacta a funded company?

Avacta is a funded company, having raised an undisclosed amount across 13 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Jan 12, 2011.

When was the latest funding round of Avacta?

Avacta's latest funding was a $***** Post IPO round on Oct 20, 2025, with participation from 0 investor.

What is the annual revenue of Avacta?

Annual revenue of Avacta is less than £1M as on Dec 31, 2024

Where does Avacta rank among its competitors?

Avacta ranks 655th amongst 3318 active competitors, of which 1118 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Avacta?

Avacta's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Avacta - 2026 Company Profile, Team, Funding, Competitors & Financials

Avacta is a public company based in London (United Kingdom), founded in 2006. It operates as a Developer of drug delivery technology using tumor activated peptide linkers. Avacta has raised an undisclosed amount in funding. The company has 3318 active competitors, including 1118 funded and 780 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of drug delivery technology using tumor activated peptide linkers. This technology attaches peptides to existing therapeutic agents to maintain them in an inactive state while circulating in the bloodstream. The drug remains inactive until it reaches the tumor site, where specific enzymes remove the peptide to release the active medication. This mechanism concentrates the therapeutic effect within the tumor environment.

Website: avacta.com
Social
Email ID: *****@avacta.com
Phone Number: +44 **********
Registered Address: THE COMPANY SECRETARY,UNIT 20 ASH WAY,THORP ARCH ESTATE,WETHERBY,ENGLAND,LS23 7FA

Key Metrics

Founded Year

2006

Location

London, United Kingdom

Stage

Public

Latest Funding Round

Post IPO, Oct 20, 2025, $*****

Investors

WG Partners & 3 more

Ranked

655^th among 3318 active competitors

Annual Revenue

£0 - £1M as on Dec 31, 2024

Employee Count

48 as on Sep 30, 2026

Investment & Acquisitions

curidium.com

Similar Companies

Jazz Pharmaceuticals & 2989 more

Exit Details

Public

View Avacta's full profile

Avacta is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Avacta Group Plc CIN: 4748597 , United Kingdom, Active	Apr 28, 2003	£0 - £1M (As on Dec 31, 2024)	-
Avacta Life Sciences Limited CIN: 6605196 , Germany, Active	May 28, 2008	-	86 (As on Dec 31, 2021)

Avacta got listed on Aug 08, 2006.

Click here to take a look at Avacta's IPO in detail

Avacta has raised funding over 13 rounds. Its first funding round was on Jan 12, 2011. Avacta has 4 institutional investors.

Here is the list of recent funding rounds of Avacta:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 20, 2025	2485170	Post IPO	3897609	2770027	1795998	4061654
Aug 29, 2025	3214458	Post IPO	2798273	2282905	5784592	3741973
Feb 29, 2024	7942112	Post IPO	1528241	3582116	4076857	6911303

Access funding benchmarks and valuations. Sign up today!

View details of Avacta's funding rounds and investors

Avacta's employee count trend

Avacta has 48 employees as of Sep 26. Here is Avacta's employee count trend over the years:

Uncover Avacta's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Avacta include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Avacta, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
655th	Avacta 2006, London (United Kingdom), Public	Developer of drug delivery technology using tumor activated peptide linkers	-	WG Partners, IP Group & 2 others	48/100